Roseola epidemiology and demographics

Roseola Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Roseola from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Roseola epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Roseola epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Roseola epidemiology and demographics
CDC on Roseola epidemiology and demographics
Roseola epidemiology and demographics in the news
Blogs on Roseola epidemiology and demographics
Directions to Hospitals Treating Type chapter name here
Risk calculators and risk factors for Roseola epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Epidemiology and demographics

Prevalence

• HHV-6 infection is detected in more than 90% of adult populations in developed countries.

Age

Roseola commonly affects young children between the ages of 7 and 13 months.

Gender

• Roseola occurs equally in boys and girls.

Race

• There is no racial predilection for roseola.

Developed countries

• HHV6 infection is nearly universal accounting for 10-45% of febrile illness in infants.

Developing countries

There is a strong association of HHV6A in Zambian children when compared to rest of the world.